New tests launched in May


New Tests

In May 2023, Mayo Clinic Laboratories announced 22 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched by Mayo Clinic Laboratories:

BETA2 | Beta-2 Transferrin: Detection of Spinal Fluid in Other Body Fluid

Detection of spinal fluid in body fluids, such as ear or nasal fluid.

BILAO | Biliary Tract Malignancy, FISH, Varies

Assessing bile duct brushing or hepatobiliary brushing specimens for malignancy.

FBILM | Biliary Tract Malignancy-Cytology, FISH, Varies

Assessing bile duct brushing or hepatobiliary brushing specimens for malignancy.

HEXLA | Hexagonal Lupus Anticoagulant, Plasma

Confirming or excluding the presence of a lupus anticoagulant (LA), in conjunction with other appropriate coagulation tests.

Differentiating between deficiencies or inhibitors of specific coagulation factors and LA inhibitors.

Evaluating a prolonged activated partial thromboplastin time resulting from inhibition.

HIP12 | HIV-1/HIV-2 RNA Detection, Plasma

Diagnosis of HIV-1 and/or HIV-2 infection in individuals with indeterminate or inconclusive HIV serologic test results.

Diagnosis of HIV-1 and/or HIV-2 infection in individuals with acute or early HIV-1 and/or HIV-2 infection.

Diagnosis of HIV-1 and/or HIV-2 infection in infants under 18 months of age who are born to HIV-infected mothers.

HIS12 | HIV-1/HIV-2 RNA Detection, Serum

Diagnosis of HIV-1 and/or HIV-2 infection in individuals with indeterminate or inconclusive HIV serologic test results.

Diagnosis of HIV-1 and/or HIV-2 infection in individuals with acute or early HIV-1 and/or HIV-2 infection.

Diagnosis of HIV-1 and/or HIV-2 infection in infants under 18 months of age who are born to HIV-infected mothers.

HIVDI | HIV-1 and HIV-2 Antibody Confirmation and Differentiation, Serum

Confirmation and differentiation of HIV-1 and HIV-2 antibodies in serum specimens that show reactive results with third-(HIV-1/-2 antibody only) and 4th-generation (HIV antigen and antibody) HIV serologic assays.

Confirmation and differentiation of HIV-1 and HIV-2 antibodies in cadaveric blood or hemolyzed serum specimens that show reactive results with initial HIV serologic screening assays.

This test is not useful as a screening test for HIV infection in symptomatic or asymptomatic individuals. It is not to be used as a screening or confirmatory test for blood donor specimens.

This test is not useful for maternal or newborn HIV screening for specimens originating in New York State.

HIVDS | HIV-1 and HIV-2 Antigen and Antibody Diagnostic Evaluation, Serum

Diagnosing HIV-1 and/or HIV-2 infection in symptomatic patients more than 2 years old.

Follow-up testing of individuals with reactive rapid HIV test results.

This test should not be used as a screening or confirmatory test for blood donor specimens.

HIVSS | HIV-1 and HIV-2 Antigen and Antibody Routine Screen, Serum

Screening for HIV-1 and HIV-2 infection in nonsymptomatic, nonpregnant individuals older than 2 years.

This test should not be used as a screening or confirmatory test for blood donor specimens.

HPP12 | HIV-1/HIV-2 RNA Detection Prenatal, Plasma

Diagnosis of HIV-1 and/or HIV-2 infection in pregnant individuals with indeterminate or inconclusive HIV serologic test results.

Diagnosis of HIV-1 and/or HIV-2 infection in pregnant individuals in the acute or early phase of HIV-1 and/or HIV-2 infection.

HPS12 | HIV-1/HIV-2 RNA Detection Prenatal, Serum

Diagnosis of HIV-1 and/or HIV-2 infection in pregnant individuals with indeterminate or inconclusive HIV serologic test results.

Diagnosis of HIV-1 and/or HIV-2 infection in pregnant individuals in the acute or early phase of HIV-1 and/or HIV-2 infection.

HVPPS | HIV-1 and HIV-2 Antibody Confirmation and Differentiation Prenatal, Serum

Confirmation and differentiation of HIV-1 and HIV-2 antibodies in serum specimens from prenatal patients who show reactive results with 3rd- (HIV-1/-2 antibody only) and 4th-generation (HIV antigen and antibody) HIV serologic assays.

This test is not useful as a screening test for HIV infection in symptomatic or asymptomatic individuals.

This test should not be used as a screening or confirmatory test for blood donor specimens.

HVPRS | HIV Antigen and Antibody Prenatal Routine Screen, Serum

Screening for HIV-1 and/or HIV-2 infection in nonsymptomatic pregnant patients.

This test should not be used as a screening or confirmatory test for blood donor specimens.

MPQU | Monoclonal Protein Quantitation, 24 Hour, Urine

Monitoring patients with monoclonal gammopathies using 24-hour urine collections.

MPU | Monoclonal Protein Studies, 24 Hour, Urine

Monitoring patients with monoclonal gammopathies.

RMPQU | Monoclonal Protein Quantitation, Random, Urine

Identifying monoclonal gammopathies using random urine specimens.

RMPU | Monoclonal Protein Studies, Random, Urine

Identifying monoclonal gammopathies using random urine specimens.

RSMPU | Monoclonal Protein Screen, Random, Urine

Identifying monoclonal gammopathies using random urine specimens.

SFX | Protein S Activity, Plasma

Second-order testing for diagnosis of congenital or acquired protein S deficiency, ie, as an adjunct to initial testing based on results of protein S antigen assay (free protein S antigen, with or without total protein S antigen assay).

Evaluating patients with a history of venous thromboembolism.

SMPU | Monoclonal Protein Screen, 24 Hour, Urine

Monitoring patients with monoclonal gammopathies.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.